Signal CRISPR moves from rare blood disorders towards common cardiovascular risk

Summary

The approved CRISPR therapy for sickle cell disease and beta thalassaemia now runs at 50 treatment sites across three regions, and a clinical study reports a 50% average reduction in LDL cholesterol within two weeks, sustained for 60 days.